NCT07885319
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Secondary endpoints revised (5)
- Notable Recruitment opened
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose-Limiting Toxicities in Phase 1b
Timeframe: From the first dose through Day 28.
Objective Response Rate
Timeframe: From the first dose through the last available tumor response assessment, up to 24 months.
Secondary (5)
Treatment-Related Adverse Events
Disease Control Rate
Progression-Free Survival
Overall Survival
Duration of Response
Arms and interventions
Ivonescimab Plus Pemetrexed and Platinum-Based ChemotherapyExperimental
A single experimental arm consisting of a Phase 1b fixed-dose expansion followed by a Phase 2 efficacy evaluation.
Drugs: Ivonescimab Combined With Chemotherapy
Sites
3 sites in 1 country